Log In
Print
BCIQ
Print
Print this Print this
 

dabigatran antidote, idarucizumab (BI 655075)

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionFab fragment against dabigatran
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentRegistration
Standard IndicationBleeding
Indication DetailsReverse anticoagulant activity of dabigatran
Regulatory Designation U.S. - Accelerated Approval (Reverse anticoagulant activity of dabigatran);
U.S. - Breakthrough Therapy (Reverse anticoagulant activity of dabigatran);
U.S. - Priority Review (Reverse anticoagulant activity of dabigatran)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today